Is your drug discovery ready for AI? A maturity model for GenAI in drug discovery

​The promise of AI in drug discovery is immense, but the path to realizing its full potential remains unclear for many organizations. After working with 21+ biopharma companies and 30+ active programs, we've identified emerging patterns in how organizations succeed with GenAI in protein engineering.

​This webinar shares our initial framework – not as a complete maturity model, but as a starting point for understanding the journey ahead. Cradle's CEO Stef van Grieken will present our early analysis of what separates organizations achieving 12x faster development from those still finding their way.

​We’ll discuss:
​- Our initial framework mapping the GenAI adoption journey in protein engineering
​Six key dimensions we've observed that impact success
​Common patterns and pitfalls across the industry
​Why "lab in the loop" is critical for protein AI (unlike language models)
​Real-world observations from leading pharma and biotech companies

​Most importantly: This is the beginning of a dialogue. We're sharing our analysis to spark conversation about how our industry can collectively define and achieve GenAI excellence.

​Who is this interesting for?
​- R&D leaders in biopharma
​Heads of Protein Engineering and Biologics
​Computational Biology Leaders
​Innovation and Digital Transformation Officers
​Anyone driving AI adoption in therapeutic development